Abstract: The invention includes a thioamide-modified peptide, wherein the thioamide modification increases the in vivo half-life of the peptide. The invention further includes methods of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering to the subject a thioamide-modified peptide of the invention.
Type:
Grant
Filed:
February 12, 2021
Date of Patent:
February 6, 2024
Assignees:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Abstract: Disclosed herein are a means to prevent and/or ameliorate age, disease and obesity associated metabolic diseases, such as diabetes and impaired glucose tolerance. Also disclosed are compositions and methods that relate to the findings that GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis in aged mice administered a high fat diet. In particular, the methods and compositions described herein relate to increasing the level of GDF11 in a subject, thereby treating or preventing the development of obesity in the subject, reducing the metabolic consequences of obesity and improving the subject's metabolic health.
Type:
Grant
Filed:
March 16, 2021
Date of Patent:
February 6, 2024
Assignees:
President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.
Inventors:
Ornella Barrandon, Tommaso Poggioli, Douglas A. Melton, Richard T. Lee
Abstract: The present invention provides glycated Amadori products of the CD59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated Amadori products of CD59 and fragments thereof to be used for the generation of antibodies and antibody fragments. Still other aspects of the invention include methodologies for the preparation of glycated Amadori products of CD59, fragments thereof, the inventive antibodies, and antibody fragments.
Type:
Grant
Filed:
November 1, 2021
Date of Patent:
February 6, 2024
Assignee:
President and Fellows of Harvard College
Abstract: An evaporative cooling system includes a porous ceramic body with a plurality of dry channels and a plurality of wet channels. The plurality of dry channels are configured to inhibit transfer of water vapor into the dry channels and include a barrier layer that includes a roughened layer with a features size less than 1000 nm and a hydrophobic chemical modification disposed on the roughened layer. The plurality of wet channels are configured to allow transfer of water vapor.
Type:
Grant
Filed:
February 24, 2022
Date of Patent:
February 6, 2024
Assignee:
President and Fellows of Harvard College
Inventors:
Jonathan L. Grinham, Jack Alvarenga, Martin Bechthold, Joanna Aizenberg
Abstract: The technology described herein is directed to pharmaceutical compositions comprising at least one Scg2 neuropeptide, as well as cell culture media or kits comprising such Scg2 neuropeptides. Also described herein are nucleic acids, vectors, or viral vectors encoding at least one Scg2 neuropeptide. In further aspects, described herein are methods of treating a memory-associated disorder, a learning disability, a neurodegenerative disease or disorder, or epilepsy with a pharmaceutical composition, nucleic acid, vector, or viral vector as described herein. In further aspects, described herein are detection methods of memory-associated analytes, such as Scg2 neuropeptides.
Type:
Application
Filed:
December 6, 2021
Publication date:
February 1, 2024
Applicant:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems.
Type:
Application
Filed:
December 27, 2022
Publication date:
February 1, 2024
Applicants:
The Broad Institute, Inc., Massachusetts Institute of Technology, University of Tokyo, President and Fellows of Harvard College
Inventors:
Silvana KONERMANN, Alexandro TREVINO, Mark BRIGHAM, Fei RAN, Patrick HSU, Chie-yu LIN, Osamu NUREKI, Hiroshi NISHIMASU, Ryuichiro ISHITANI, Feng ZHANG
Abstract: Some aspects of this disclosure provide compositions, strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins capable of inducing a cytosine (C) to guanine (G) change in a nucleic acid (e.g., genomic DNA) are provided. In some embodiments, fusion proteins of a nucleic acid programmable DNA binding protein (e.g., Cas9) and nucleic acid editing proteins or protein domains, e.g., deaminase domains, polymerase domains, and/or base excision enzymes are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a nucleic acid programmable DNA binding protein (e.g., Cas9), and nucleic acid editing proteins or domains, are provided.
Type:
Application
Filed:
November 28, 2022
Publication date:
February 1, 2024
Applicant:
President and Fellows of Harvard College
Abstract: The embodiments of the invention described herein relate to systems and methods for culturing and/or maintaining intestinal cells, tissues and/or organoids in vitro. The cells, tissues and/or organoids cultured according to the methods and systems described herein can mimic or reproduce natural intestinal epithelial structures and behavior as well as support co-culture of intestinal microflora.
Type:
Grant
Filed:
November 19, 2019
Date of Patent:
January 30, 2024
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Abstract: Provided herein are compositions and methods comprising engineered microorganisms and their use for locally degrading an antibiotic in the gastrointestinal tract to prevent or limit death of beneficial flora.
Type:
Application
Filed:
December 1, 2021
Publication date:
January 25, 2024
Applicants:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Inventors:
Andres Fernando CUBILLOS, James J COLLINS
Abstract: The present invention provides capsules having a shell of material that comprises an assembly of a protein, and the capsule is optionally provided with a network of material within the shell that is an assembly of the protein. The assembly of the protein is obtained or obtainable by the aggregation of the protein, optionally together with another protein. The assembly is a non-covalent assembly of a protein.
Type:
Grant
Filed:
September 4, 2015
Date of Patent:
January 23, 2024
Assignees:
CAMBRIDGE ENTERPRISE LIMITED, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Tuomas Knowles, Ulyana Shimanovich, Christopher Dobson, David Weitz
Abstract: The present disclosure, at least in part, provides a dual-AAV vector system and compositions thereof for expression full-length PCDH15 in target cells. The present disclosure also provides the method of using the dual rAAV system for delivering full-length PCDH15 to a target cell (e.g., inner cells or cells in the eye) for treating deafness and/or blindness (e.g., Usher syndrome 1F).
Type:
Application
Filed:
September 14, 2021
Publication date:
January 18, 2024
Applicant:
President and Fellows of Harvard College
Inventors:
David P. Corey, Eric M. Mulhall, Maryna V. Ivanchenko
Abstract: Disclosed herein are methods and systems for correlating continuous physiological processes (e.g., electrophysiological activity) and biomolecular processes (e.g., gene expression) in cells within a tissue. Also disclosed herein are methods for preparing a tissue for continuous electrophysiological recording. Further disclosed herein are systems comprising nanoelectronic devices within cells in a tissue, wherein each nanoelectronic device comprises a unique electronic barcode. The methods and systems described herein comprise any tissue with electrical activity (e.g., brain tissue, heart tissue, nervous system tissue, muscle tissue, pancreas tissue, or gastrointestinal tract tissue). Additionally disclosed herein are methods for disease modeling, methods for discovering a target for treating a disease, and methods for drug screening.
Type:
Application
Filed:
October 27, 2021
Publication date:
January 18, 2024
Applicants:
The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
Abstract: An organ-on-a-chip microfluidic device is disclosed that mimics a human lymph node and/or human lymphoid tissue. The device can include cells from human blood and lymphatic tissue, include an extracellular matrix for the development of immune system components, and provide for the perfusion of fluids and solids resembling blood and lymphatic fluid within micrometer sized channels.
Type:
Grant
Filed:
April 27, 2022
Date of Patent:
January 9, 2024
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Abstract: Provided herein are compounds useful for the treatment of various parasitic diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compostions, veterinary compositions and may be used in methods of treatment and/or prophylaxis of diseases spread by parasites, including malaria and cryptosporidiosis.
Type:
Grant
Filed:
July 28, 2021
Date of Patent:
January 9, 2024
Assignees:
THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Eamon Comer, Nobutaka Kato, Marshall Morningstar, Bruno Melillo
Abstract: The invention provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a DNA-targeting Cpf1 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof.
Type:
Grant
Filed:
May 18, 2018
Date of Patent:
January 9, 2024
Assignees:
THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Feng Zhang, David Benjamin Turitz Cox, Jonathan Gootenberg, Omar O. Abudayyeh, Bernd Zetsche, Jonathan Strecker
Abstract: The present disclosure provides an optical component, which may be a metasurface grating, including (a) a substrate; and (b) an array of subwavelength-spaced phase-shifting elements, which are tessellated on the substrate to produce, when illuminated with a polarized incident light, a diffracted light beam with a distinct polarization state for each of a finite number of diffraction orders, wherein the finite number is 2 or more.
Type:
Grant
Filed:
October 13, 2021
Date of Patent:
January 9, 2024
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Abstract: Method for making a coating on a surface of a substrate are described herein. The methods include applying a mixture to a surface of a substrate while maintaining the substrate at an elevated temperature. The mixture includes a particulate material and a proteinaceous material.
Type:
Application
Filed:
November 29, 2021
Publication date:
January 4, 2024
Applicant:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Pawan JOLLY, Sanjay Sharma TIMILSINA, Nolan DURR, Donald E. INGBER